Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 18-Nov-24 4:31 PM View:  | Miller Mary Chief Legal Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Nov-24 | Payment of Exercise | 184 | $7.92 | $1,457.28 | (< 1%) 38.13K to 37.94K | |
| 18-Nov-24 10:00 PM View: | Devroe Eric Chief Operating Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Nov-24 | Payment of Exercise | 613 | $7.92 | $4,854.96 | (< 1%) 68.48K to 67.87K | |
| 18-Nov-24 10:00 PM View: | Gamelin Erick Chief Development Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Nov-24 | Payment of Exercise | 402 | $7.92 | $3,183.84 | (2%) 17.36K to 16.96K | |
| 18-Nov-24 4:32 PM View: | Peterson Katharine Chief Accounting Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Nov-24 | Payment of Exercise | 99 | $7.92 | $784.08 | (2%) 4.63K to 4.54K | |
| 23-Aug-24 4:11 PM View: | Blume-Jensen Peter President and CEO Director | Acrivon Therapeutics, Inc. (ACRV) | 21-Aug-24 | Payment of Exercise | 79,616 | $9.19 | $731,671.00 | (3%) 2.82M to 2.74M | |
| 16-Aug-24 4:52 PM View: | Masson Kristina EVP - Business Operations Director | Acrivon Therapeutics, Inc. (ACRV) | 14-Aug-24 | Payment of Exercise | 490 | $7.02 | $3,439.80 | (< 1%) 2.82M to 2.82M | |
| 16-Aug-24 4:52 PM View: | Miller Mary Chief Legal Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Aug-24 | Payment of Exercise | 184 | $7.02 | $1,291.68 | (< 1%) 39.15K to 38.97K | |
| 16-Aug-24 4:48 PM View: | Devroe Eric Chief Operating Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Aug-24 | Payment of Exercise | 613 | $7.02 | $4,303.26 | (< 1%) 69.1K to 68.48K | |
| 16-Aug-24 4:50 PM View: | Gamelin Erick Chief Development Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Aug-24 | Payment of Exercise | 402 | $7.02 | $2,822.04 | (2%) 17.77K to 17.36K | |
| 16-Aug-24 4:53 PM View: | Peterson Katharine Chief Accounting Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Aug-24 | Payment of Exercise | 99 | $7.02 | $694.98 | (2%) 4.73K to 4.63K | |
| 16-Aug-24 4:47 PM View: | Blume-Jensen Peter President and CEO Director | Acrivon Therapeutics, Inc. (ACRV) | 14-Aug-24 | Payment of Exercise | 59,765 | $7.02 | $419,550.00 | (2%) 2.88M to 2.82M | |
| 16-Aug-24 4:51 PM View: | Holm-Jorgensen Rasmus Chief Financial Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Aug-24 | Payment of Exercise | 368 | $7.02 | $2,583.36 | (1%) 27.26K to 26.89K | |
| 19-Jul-24 4:20 PM View: | Miller Mary Chief Legal Officer | Acrivon Therapeutics, Inc. (ACRV) | 17-Jul-24 | Payment of Exercise | 558 | $7.69 | $4,291.02 | (1%) 39.71K to 39.15K | |
| 21-May-24 4:04 PM View: | Devroe Eric Chief Operating Officer | Acrivon Therapeutics, Inc. (ACRV) | 17-May-24 | Option Exercise | 10,000 | $1.04 | $10,400.00 | 17% 59.1K to 69.1K | |
| 16-May-24 6:58 PM View: | Gamelin Erick Chief Development Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-May-24 | Payment of Exercise | 402 | $8.36 | $3,360.72 | (2%) 18.17K to 17.77K | |
| 16-May-24 7:05 PM View: | Peterson Katharine Chief Accounting Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-May-24 | Payment of Exercise | 99 | $8.36 | $827.64 | (2%) 4.83K to 4.73K | |
| 16-May-24 6:54 PM View: | Blume-Jensen Peter President and CEO Director | Acrivon Therapeutics, Inc. (ACRV) | 14-May-24 | Payment of Exercise | 54,918 | $8.36 | $459,114.00 | (2%) 2.93M to 2.88M | |
| 16-May-24 7:03 PM View: | Miller Mary Chief Legal Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-May-24 | Payment of Exercise | 184 | $8.36 | $1,538.24 | (< 1%) 39.89K to 39.71K | |
| 16-May-24 7:00 PM View: | Holm-Jorgensen Rasmus Chief Financial Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-May-24 | Payment of Exercise | 368 | $8.36 | $3,076.48 | (1%) 27.63K to 27.26K | |
| 16-May-24 6:56 PM View: | Devroe Eric Chief Operating Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-May-24 | Payment of Exercise | 613 | $8.36 | $5,124.68 | (1%) 59.71K to 59.1K | |
| 16-May-24 7:02 PM View: | Masson Kristina EVP - Business Operations Director | Acrivon Therapeutics, Inc. (ACRV) | 14-May-24 | Payment of Exercise | 490 | $8.36 | $4,096.40 | (< 1%) 2.88M to 2.88M | |
| 19-Apr-24 4:10 PM View: | Miller Mary Chief Legal Officer | Acrivon Therapeutics, Inc. (ACRV) | 17-Apr-24 | Payment of Exercise | 558 | $10.34 | $5,769.72 | (1%) 40.45K to 39.89K | |
| 15-Apr-24 8:53 AM View: | Perceptive Advisors LLC 10% Owner | Acrivon Therapeutics, Inc. (ACRV) | 11-Apr-24 | Private Purchase | 2,353,000 | $8.50 | $20,000,500.00 | 78% 3.01M to 5.36M | |
| 15-Apr-24 4:15 PM View: | Ra Capital Management, LLC Director 10% Owner | Acrivon Therapeutics, Inc. (ACRV) | 11-Apr-24 | Grant | 3,530,000 | $8.50 | $30,005,000.00 | 73% 4.81M to 8.34M | |
| 16-Feb-24 5:12 PM View: | Holm-Jorgensen Rasmus Chief Financial Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Feb-24 | Payment of Exercise | 434 | $3.40 | $1,475.60 | (2%) 28.06K to 27.63K | |
| 16-Feb-24 5:08 PM View: | Devroe Eric Chief Operating Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Feb-24 | Payment of Exercise | 723 | $3.40 | $2,458.20 | (1%) 60.43K to 59.71K | |
| 16-Feb-24 5:13 PM View: | Masson Kristina EVP - Business Operations Director | Acrivon Therapeutics, Inc. (ACRV) | 14-Feb-24 | Payment of Exercise | 579 | $3.40 | $1,968.60 | (< 1%) 2.94M to 2.94M | |
| 16-Feb-24 5:14 PM View: | Miller Mary Chief Legal Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Feb-24 | Payment of Exercise | 217 | $3.40 | $737.80 | (< 1%) 40.67K to 40.45K | |
| 16-Feb-24 5:10 PM View: | Gamelin Erick Chief Development Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Feb-24 | Payment of Exercise | 468 | $3.40 | $1,591.20 | (3%) 18.64K to 18.17K | |
| 16-Feb-24 5:06 PM View: | Blume-Jensen Peter President and CEO Director | Acrivon Therapeutics, Inc. (ACRV) | 14-Feb-24 | Payment of Exercise | 41,861 | $3.40 | $142,327.00 | (1%) 2.98M to 2.94M | |
| 19-Jan-24 4:24 PM View: | Miller Mary Chief Legal Officer | Acrivon Therapeutics, Inc. (ACRV) | 17-Jan-24 | Payment of Exercise | 652 | $4.35 | $2,836.20 | (2%) 41.32K to 40.67K | |
| 16-Nov-23 7:42 PM View: | Masson Kristina EVP - Business Operations Director | Acrivon Therapeutics, Inc. (ACRV) | 14-Nov-23 | Payment of Exercise | 1,900 | $5.08 | $9,652.00 | (< 1%) 2.98M to 2.98M | |
| 16-Nov-23 7:43 PM View: | Miller Mary Chief Legal Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Nov-23 | Payment of Exercise | 735 | $5.08 | $3,733.80 | (2%) 42.05K to 41.32K | |
| 16-Nov-23 7:41 PM View: | Gamelin Erick Chief Medical Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Nov-23 | Payment of Exercise | 1,395 | $5.08 | $7,086.60 | (7%) 20.03K to 18.64K | |
| 16-Nov-23 7:41 PM View: | Blume-Jensen Peter President and CEO Director | Acrivon Therapeutics, Inc. (ACRV) | 14-Nov-23 | Payment of Exercise | 239,023 | $5.08 | $1,214,240.00 | (7%) 3.22M to 2.98M | |
| 16-Nov-23 7:42 PM View: | Holm-Jorgensen Rasmus Chief Financial Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Nov-23 | Payment of Exercise | 1,470 | $5.08 | $7,467.60 | (5%) 29.53K to 28.06K | |
| 16-Nov-23 7:41 PM View: | Devroe Eric Chief Operating Officer | Acrivon Therapeutics, Inc. (ACRV) | 14-Nov-23 | Payment of Exercise | 2,450 | $5.08 | $12,446.00 | (4%) 62.88K to 60.43K | |
| 19-Oct-23 7:45 PM View: | Miller Mary Chief Legal Officer | Acrivon Therapeutics, Inc. (ACRV) | 17-Oct-23 | Payment of Exercise | 2,232 | $5.48 | $12,231.40 | (5%) 44.29K to 42.05K | |
| 28-Sep-23 7:17 PM View: | Miller Mary Chief Legal Officer | Acrivon Therapeutics, Inc. (ACRV) | 26-Sep-23 | Grant | 3,858 | -- | -- | 10% 40.43K to 44.29K | |
| 23-Aug-23 4:19 PM View: | Blume-Jensen Peter President and CEO Director | Acrivon Therapeutics, Inc. (ACRV) | 21-Aug-23 | Grant | 493,994 | -- | -- | 18% 2.72M to 3.22M | |
| 28-Jun-23 3:47 PM View: | Chione Ltd 10% Owner | Acrivon Therapeutics, Inc. (ACRV) | 26-Jun-23 | Market Sale | 16 | $12.93 | $206.88 | (< 1%) 3.85M to 3.85M | 3% |
| 14-Jun-23 6:33 PM View: | Chione Ltd 10% Owner | Acrivon Therapeutics, Inc. (ACRV) | 14-Jun-23 | Market Sale | 893 | $12.13 | $10,832.10 | (< 1%) 3.85M to 3.85M | (3%) |
| 14-Jun-23 6:33 PM View: | Chione Ltd 10% Owner | Acrivon Therapeutics, Inc. (ACRV) | 13-Jun-23 | Market Sale | 3,000 | $12.30 | $36,900.00 | (< 1%) 3.85M to 3.85M | (2%) |
| 14-Jun-23 6:33 PM View: | Chione Ltd 10% Owner | Acrivon Therapeutics, Inc. (ACRV) | 12-Jun-23 | Market Sale | 2,000 | $12.34 | $24,680.00 | (< 1%) 3.86M to 3.85M | (1%) |
| 06-Jun-23 4:15 PM View: | Devroe Eric Chief Operating Officer | Acrivon Therapeutics, Inc. (ACRV) | 05-Jun-23 | Option Exercise | 9,225 | $1.04 | $9,594.00 | 17% 53.66K to 62.88K | |
| 01-Jun-23 8:40 PM View: | Blume-Jensen Peter President and CEO Director | Acrivon Therapeutics, Inc. (ACRV) | 31-May-23 | Option Exercise | 33,605 | $3.88 | $130,387.00 | 1% 2.69M to 2.72M | |
| 21-Nov-22 6:26 PM View: | Chione Ltd 10% Owner | Acrivon Therapeutics, Inc. (ACRV) | 17-Nov-22 | Private Purchase | 400,000 | $12.50 | $5,000,000.00 | 12% 3.46M to 3.86M | |
| 21-Nov-22 4:31 PM View: | Ra Capital Management, LLC Director 10% Owner | Acrivon Therapeutics, Inc. (ACRV) | 17-Nov-22 | Conversion | 1,421,010 | -- | -- | 100% 0 to 1.42M | |
| 21-Nov-22 1:22 PM View: | Wellington Biomedical Innov... 10% Owner | Acrivon Therapeutics, Inc. (ACRV) | 17-Nov-22 | Conversion | 888,130 | -- | -- | 100% 0 to 888.13K | |
| 21-Nov-22 4:31 PM View: | Ra Capital Management, LLC Director 10% Owner | Acrivon Therapeutics, Inc. (ACRV) | 17-Nov-22 | Private Purchase | 3,389,500 | $12.50 | $42,368,800.00 | 239% 1.42M to 4.81M |
